Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 579-584

  Deeb, George ^a   Vaughan, Mary M ^a   McInnis, Ian ^a   Ford, Laurie Ann ^a   Sait, Sheila N J ^a   Starostik, Petr ^a   Wetzler, Meir ^a   Mashtare, Terry ^a,b   Wang, Eunice S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Acute myeloid leukemia; HIF 1 ; Hypoxia; Marrow immunohistochemistry; VEGF

Indexed keywords

ANTHRACYCLINE; CYTARABINE; FLT3 LIGAND; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NUCLEOPHOSMIN; VASCULOTROPIN A; VASCULOTROPIN C;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UBIQUITINATION;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79954591044     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.020     Document Type: Article

References (48)

1. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-732.
2. Selvendiran K., Bratasz A., Kuppusamy M.L., Tazi M.F., Rivera B.K., Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 2009, 125(9):2198-2204.
3. Fiegl M., Samudio I., Mnjoyan Z., Korchin B., Fritsche H., Andreeff M. Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia 2010, 24(7):1364-1367.
4. Colla S., Storti P., Donofrio G., Todoerti K., Bolzoni M., Lassaretti M., et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 2010.
5. Harrison J.S., Rameshwar P., Chang V., Bandari P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 2002, 99(1):394.
6. Eliasson P., Jonsson J. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 2010, 222(1):17-22.
7. Song L.P., Zhang J., Wu S.F., Huang Y., Zhao Q., Cao J.P., et al. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene 2008, 27(4):519-527.
8. Hatfield K.J., Bedringsaas S.L., Ryningen A., Gjertsen B.T., Bruserud O. Hypoxia increases HIF-1alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw 2010.
9. Rabitsch W., Sperr W.R., Lechner K., Chott A., Prinz E., Valent P., et al. Bone marrow microvessel density and its prognostic significance in AML. Leuk Lymphoma 2004, 45(7):1369-1373.
10. Aguayo A., Estey E., Kantarjian H., Mansouri T., Gidel C., Keating M., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999, 94(11):3717-3721.
11. de Bont E.S., Neefjes V.M., Rosati S., Vellenga E., Kamps W.A. New vessel formation and aberrant VEGF/VEGFR signaling in acute leukemia: does it matter?. Leuk Lymphoma 2002, 43(10):1901-1909.
12. Chien M.H., Ku C.C., Johansson G., Chen M.W., Haiao M., Su J.L., et al. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 2009, 30(12):2005-2013.
13. Dias S., Choy M., Alitalo K., Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002, 99(6):2179-2184.
14. de Jonge H.J., Valk P.J., Veeger N.J., Chen M.W., Haiao M., Su J.L., et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010, 110(10):1747-1754.
15. Sreenivasulu C., Toth K., Cao S., Durrani F.A., Vaughan M.M., Jensen R.L., et al. Se-methylselenocysteine sensitizes hypoxic cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol 2010, 66(5):899-911.
16. Murphy K.M., Levis M., Hafez M.J., Geiger T., Cooper L.C., Smith B.D., et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 2003, 5(2):96-102.
17. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria. Treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21(24):4642-4649.
18. Aguayo A., Kantarjian H.M., Estey E.H., Giles F.J., Verstovsek S., Manshouri T., et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002, 95(9):1923-1930.
19. Fragoso R., Elias A.P., Dias S. Autocrine VEGF loops, signaling pathways, and acute leukemia regulation. Leuk Lymphoma 2007, 48(3):481-488.
20. Tomita M., Semenza G.L., Michiels C., Matsuda T., Uchihara J.N., Okudaira T., et al. Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells. Biochem J 2007, 406(2):317-323.
21. Wellmann S., Guschmann M., Griethe W., Eckert C., von Stackelberg A., Lottaz C., et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004, 18(5):926-933.
22. Zheng X., Ruas J.L., Cao R., Poellinger L., Pereira T. Cell-type-specific regulation of degradation of hypoxia-inducible factor 1 alpha: role of subcellular compartmentalization. Mol Cell Biol 2006, 26(12):4628-4641.
23. Du R., Lu K.V., Petritsch C., Lu K., Liu P., Haller A., et al. HIF-1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13(3):206-220.
24. Abdel-Wahab O., Levine R.L. Metabolism and the leukemic stem cell. J Exp Med 2010, 207(4):677-680.
25. Zhao F., Mancuso A., Bui T.V., Tong A., Gruber J.J., Swider C.R., et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 2010, 29(20):2962-2972.
26. Boissel N., Nibourel O., Renneville A., Gardin C., Reman O., Contentin N., et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010, 28(23):3717-3723.
27. Marcucci G., Maharry K., Wu Y.Z., Radmacher M.D., Mrozek K., Margeson D., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28(14):2348-2355.
28. Paschka P., Schlenk R.F., Gaidzik V.I., Habdank M., Kronke J., Bullinger L., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28(22):3636-3643.
29. Zhang J., Chen G.Q. Hypoxia-HIF-1alpha-C/EBPalpha/Runx1 signaling in leukemic cell differentiation. Pathophysiology 2009, 16(4):297-303.
30. Lall H., Coughlan K., Sumbayev V. HIF-1alpha protein is an essential factor for protection of myeloid cells against LPS-induced depletion of ATP and apoptosis that supports Toll-like receptor 4 mediated production of IL-6. Mol Immunol 2008, 45:3045-3049.
31. Jin G., Matsushita H., Asai S., Tsukamato H., Ono R., Nosaka T., et al. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun 2009, 390(3):1001-1006.
32. Hoffmann A.C., Danenberg K.D., Taubert H., Danenberg P.V., Wuerl P. A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res 2009, 15(16):5191-5198.
33. Dorevic G., Matusan-Ilijas K., Babarovic E., Hadzisejdic I., Grahovac M., Grahovac B., et al. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2009, 28:40.
34. Schoppmann S.F., Fenzl A., Schindl M., Bachleitner-Hofmann T., Nagy K., Gnant M., et al. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res Treat 2006, 99(2):135-141.
35. Katsuta M., Miyashita M., Makino H., Nomura T., Shinji S., Yamashita K., et al. Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol 2005, 78(2):123-130.
36. Liang X., Yang D., Hu J., Hao X., Gao J., Mao Z. Hypoxia inducible factor-1alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 2008, 28(3A):1659-1666.
37. Liersch R., Schliemann C., Bieker R., Hintelmann H., Buechner T., Berdel W.E., et al. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk Res 2008, 32(6):954-961.
38. de Jonge H.J., Weidenaar A.C., Ter Elst A., den Boer M.L., Cloos J., de Haas V., et al. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res 2008, 14(3):924-930.
39. Fielder W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997, 11(8):1234-1237.
40. Liu L., Marti G.P., Wei X., Zhang X., Zhang H., Liu Y.V., et al. Age-dependent impairment of HIF-1alpha expression in diabetic mice: correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J Cell Physiol 2008, 217(2):319-327.
41. Frohling S., Schlenk R.F., Kayser S., Morhardt M., Benner A., Dohner K., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108(10):3280-3288.
42. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8(3):180-192.
43. Mayerhofer M., Aichberger K.J., Florian S., Krauth M.T., Hauswirth A.W., Derdak S., et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J 2005, 19(8):960-962.
44. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99(12):4326-4335.
45. Mrozek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109(2):431-448.
46. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Anthracycline chemotherapy inhibits HIF-1alpha transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009, 106(7):2353-2358.
47. Ellis L., Hammers H., Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009, 280(2):145-153.
48. Verheul H.M., Salumbides B., Van Erp K., Hammers H., Qian D.Z., Sanni T., et al. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 2008, 14(11):3589-3597.